Peri- and postnatal rodent development of Hematide, an erythropoiesis-stimulating agent

Usage of erythropoiesis-stimulating agen

Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia

✍ Alessandra Ferrajoli; Aman U. Buzdar; Yvette DeJesus; Lee Cheng; Laura B. Michau 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 627 KB

## Abstract ## BACKGROUND: In 2007, the US Food and Drug Administration (FDA) issued regulatory alerts for use of erythropoiesis‐stimulating agents (ESAs) in cancer patients with anemia after clinical trials and meta‐analysis data found that high ESA doses were associated with adverse outcomes in